Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Kyverna Therapeutics is a biopharmaceutical company developing cell therapies, primarily CAR T-cell products, to treat autoimmune diseases. Its lead candidate, KYV-101, targets B-cell-driven conditions like stiff person syndrome, myasthenia gravis, and lupus nephritis, aiming for durable remission through deep B cell depletion. The company leverages proprietary technologies, strategic partnerships, and innovative manufacturing to address unmet medical needs in autoimmune therapeutics.
This description was generated via AI from an annual report. Updated about 1 year ago.